T. Rowe Price reports a Charles River (CRL) stake with sole voting power over 2.77M shares.
Alpha Vantage · Stock Titan · · AI-summarised by FinFlash
T. Rowe Price Associates, Inc. has filed a Schedule 13G, disclosing a 6.3% beneficial ownership stake in Charles River Laboratories International, Inc. (CRL) as of September 30, 2026. The firm reported sole voting power over 2,768,367 shares and sole dispositive power over 3,010,619 shares, while explicitly denying beneficial ownership. This filing indicates a significant passive investment in Charles River.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.